Morepen Laboratories Limited Share Price & Analysis
₹42.63▼ -1.48%Updated 28 Apr 2026, 11:32 am IST
LTP
₹42.63
-1.48%
Open
₹—
High
₹43.85
Low
₹42.56
Close
₹42.63
52W High
₹70.5
52W Low
₹33
Volume
1893K
Lot Size
1
Sector
Healthcare
Market Cap
₹2K Cr
Face Value
₹2
Small Cap
Price Chart
Fundamentals
P/E
29.9
Sector P/E
41.5
P/B
1.96
EPS
₹1.82
ROE
11.8%
ROCE
15.1%
D/E Ratio
0.13
Div Yield
0.48%
Book Value
₹21.8
+
Strengths
- ✓Efficient capital deployment (ROCE 15.1%)
- ✓Attractively valued vs sector (P/E 29.9x vs industry 41.5x)
- ✓Low debt relative to equity (D/E 0.1x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,737 | ₹3.9L Cr | 32 | 5.36 | 16.9 | 20.2 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,476 | ₹1.7L Cr | 66.7 | 11.15 | 15.4 | 20.4 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,242 | ₹1.4L Cr | 60.4 | 16.97 | 26.5 | 27 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹7,797 | ₹1.1L Cr | 61.2 | 12.34 | 18.4 | 16.6 | 0.88 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,339 | ₹1.1L Cr | 19.7 | 3.1 | 18 | 22.7 | 0.16 |
| LUPIN Lupin Limited | ₹2,315 | ₹1.0L Cr | 21.1 | 5.38 | 20.6 | 21.3 | 0.32 |
| CIPLA Cipla Limited | ₹1,324 | ₹1.0L Cr | 22 | 3.24 | 17.8 | 22.7 | 0.01 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MOREPENLAB · as of Mar 2026
Promoters35.66%
FII1.94%▼0.28
DII1.67%▲0.03
Public60.72%▲0.26
Govt0.01%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 38.22% | 38.22% | 38.22% | 35.66% | 35.66% | 35.66% |
| FII | 2.11% | 1.85% | 1.67% | 2.08% | 2.22% | 1.94% |
| DII | 2.21% | 2.15% | 2.14% | 1.69% | 1.64% | 1.67% |
| Public | 57.46% | 57.76% | 57.96% | 60.57% | 60.46% | 60.72% |
| Govt | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Corporate Events
Dividend - Re 0.20 Per Share
Record: 29 Aug 2025
Dividend28 Aug 2025
Annual General Meeting
AGM19 Sept 2024
Annual General Meeting
AGM20 Sept 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹484 Cr ▲17.5% | ₹412 Cr ▼3.1% | ₹425 Cr ▼8.8% | ₹466 Cr ▲2.9% | ₹453 Cr ▲3.4% | ₹438 Cr ▼3.7% | ₹455 Cr ▲7.6% | ₹423 Cr |
| Op. Profit | ₹46 Cr ▲48.4% | ₹31 Cr ▲29.2% | ₹24 Cr ▼42.9% | ₹42 Cr ▲16.7% | ₹36 Cr ▼18.2% | ₹44 Cr ▼15.4% | ₹52 Cr ▲8.3% | ₹48 Cr |
| OPM | 10.0% ▲42.9% | 7.0% ▲16.7% | 6.0% ▼33.3% | 9.0% ▲12.5% | 8.0% ▼20.0% | 10.0% ▼9.1% | 11.0% ▲0.0% | 11.0% |
| Net Profit | ₹28 Cr ▼31.7% | ₹41 Cr ▲272.7% | ₹11 Cr ▼45.0% | ₹20 Cr ▼25.9% | ₹27 Cr ▼22.9% | ₹35 Cr ▼2.8% | ₹36 Cr ▲24.1% | ₹29 Cr |
| EPS (₹) | 0.5 ▼33.3% | 0.75 ▲275.0% | 0.2 ▼45.9% | 0.37 ▼24.5% | 0.49 ▼23.4% | 0.64 ▼9.9% | 0.71 ▲29.1% | 0.55 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.8K Cr ▲7.2% | ₹1.7K Cr ▲19.2% | ₹1.4K Cr ▼8.3% | ₹1.5K Cr ▲30.2% | ₹1.2K Cr ▲39.3% | ₹853 Cr ▲10.9% | ₹769 Cr ▲26.7% | ₹607 Cr ▲2.0% | ₹595 Cr |
| Expenses | ₹1.6K Cr ▲6.9% | ₹1.5K Cr ▲14.5% | ₹1.3K Cr ▼5.1% | ₹1.4K Cr ▲31.8% | ₹1.1K Cr ▲36.3% | ₹785 Cr ▲12.0% | ₹701 Cr ▲29.3% | ₹542 Cr ▲1.5% | ₹534 Cr |
| Op. Profit | ₹174 Cr ▲9.4% | ₹159 Cr ▲98.8% | ₹80 Cr ▼41.6% | ₹137 Cr ▲15.1% | ₹119 Cr ▲72.5% | ₹69 Cr ▲1.5% | ₹68 Cr ▲4.6% | ₹65 Cr ▲6.6% | ₹61 Cr |
| OPM | 10.0% ▲11.1% | 9.0% ▲50.0% | 6.0% ▼33.3% | 9.0% ▼10.0% | 10.0% ▲25.0% | 8.0% ▼11.1% | 9.0% ▼18.2% | 11.0% ▲10.0% | 10.0% |
| Other Income | ₹18 Cr ▲28.6% | ₹14 Cr ▲133.3% | ₹6 Cr ▼40.0% | ₹10 Cr ▼16.7% | ₹12 Cr ▲33.3% | ₹9 Cr ▲125.0% | ₹4 Cr ▲0.0% | ₹4 Cr ▲0.0% | ₹4 Cr |
| Interest | ₹8 Cr ▲100.0% | ₹4 Cr ▲100.0% | ₹2 Cr ▲128.6% | ₹-7 Cr ▼450.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▼50.0% | ₹4 Cr ▼50.0% | ₹8 Cr |
| Depreciation | ₹29 Cr ▼12.1% | ₹33 Cr ▲17.9% | ₹28 Cr ▲0.0% | ₹28 Cr ▼6.7% | ₹30 Cr ▼18.9% | ₹37 Cr ▼7.5% | ₹40 Cr ▲17.6% | ₹34 Cr ▲0.0% | ₹34 Cr |
| PBT | ₹155 Cr ▲14.8% | ₹135 Cr ▲141.1% | ₹56 Cr ▼55.9% | ₹127 Cr ▲28.3% | ₹99 Cr ▲153.8% | ₹39 Cr ▲34.5% | ₹29 Cr ▼3.3% | ₹30 Cr ▲25.0% | ₹24 Cr |
| Tax % | 24.0% ▼17.2% | 29.0% ▼6.5% | 31.0% ▲55.0% | 20.0% ▲1900.0% | 1.0% ▼92.9% | 14.0% ▲1300.0% | 1.0% | 0.0% | 0.0% |
| Net Profit | ₹118 Cr ▲21.6% | ₹97 Cr ▲148.7% | ₹39 Cr ▼61.8% | ₹102 Cr ▲5.2% | ₹97 Cr ▲185.3% | ₹34 Cr ▲17.2% | ₹29 Cr ▼3.3% | ₹30 Cr ▲25.0% | ₹24 Cr |
| EPS (₹) | 2.15 ▲14.4% | 1.88 ▲147.4% | 0.76 ▼64.3% | 2.13 ▼1.4% | 2.16 ▲188.0% | 0.75 ▲17.2% | 0.64 ▼3.0% | 0.66 ▲24.5% | 0.53 |
| Div Payout | 9.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹110 Cr ▲0.0% | ₹110 Cr ▲7.8% | ₹102 Cr ▲0.0% | ₹102 Cr ▲6.3% | ₹96 Cr ▲6.7% | ₹90 Cr ▲0.0% | ₹90 Cr ▲0.0% | ₹90 Cr ▲0.0% | ₹90 Cr ▲0.0% | ₹90 Cr |
| Reserves | ₹1.1K Cr ▲3.8% | ₹1.0K Cr ▲40.5% | ₹745 Cr ▲14.4% | ₹651 Cr ▲34.8% | ₹483 Cr ▲44.2% | ₹335 Cr ▲72.7% | ₹194 Cr ▲19.0% | ₹163 Cr ▲19.9% | ₹136 Cr ▲28.3% | ₹106 Cr |
| Borrowings | ₹158 Cr ▲50.5% | ₹105 Cr ▲262.1% | ₹29 Cr ▲16.0% | ₹25 Cr ▲31.6% | ₹19 Cr ▲11.8% | ₹17 Cr ▼87.2% | ₹133 Cr ▲0.8% | ₹132 Cr ▼1.5% | ₹134 Cr ▼20.7% | ₹169 Cr |
| Other Liabilities | ₹381 Cr ▼26.3% | ₹517 Cr ▲24.0% | ₹417 Cr ▲25.6% | ₹332 Cr ▼29.8% | ₹473 Cr ▲13.7% | ₹416 Cr ▲69.1% | ₹246 Cr ▲7.0% | ₹230 Cr ▲1.8% | ₹226 Cr ▲30.6% | ₹173 Cr |
| Total Liabilities | ₹1.7K Cr ▼2.4% | ₹1.8K Cr ▲37.5% | ₹1.3K Cr ▲16.5% | ₹1.1K Cr ▲3.7% | ₹1.1K Cr ▲24.7% | ₹858 Cr ▲29.4% | ₹663 Cr ▲7.8% | ₹615 Cr ▲4.9% | ₹586 Cr ▲8.9% | ₹538 Cr |
| Assets | ||||||||||
| Fixed Assets | ₹471 Cr ▼3.7% | ₹489 Cr ▲59.3% | ₹307 Cr ▲15.0% | ₹267 Cr ▲6.0% | ₹252 Cr ▲12.0% | ₹225 Cr ▲4.2% | ₹216 Cr ▼8.5% | ₹236 Cr ▼10.6% | ₹264 Cr ▼2.9% | ₹272 Cr |
| CWIP | ₹26 Cr ▼7.1% | ₹28 Cr ▲16.7% | ₹24 Cr ▲41.2% | ₹17 Cr ▲21.4% | ₹14 Cr ▲600.0% | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹136 Cr ▲60.0% | ₹85 Cr ▲8400.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr ▼100.0% | ₹1 Cr ▲0.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹1.1K Cr ▼6.1% | ₹1.2K Cr ▲22.5% | ₹960 Cr ▲16.1% | ₹827 Cr ▲2.9% | ₹804 Cr ▲27.4% | ₹631 Cr ▲41.5% | ₹446 Cr ▲17.7% | ₹379 Cr ▲18.1% | ₹321 Cr ▲20.7% | ₹266 Cr |
| Total Assets | ₹1.7K Cr ▼2.4% | ₹1.8K Cr ▲37.5% | ₹1.3K Cr ▲16.5% | ₹1.1K Cr ▲3.7% | ₹1.1K Cr ▲24.7% | ₹858 Cr ▲29.4% | ₹663 Cr ▲7.8% | ₹615 Cr ▲4.9% | ₹586 Cr ▲8.9% | ₹538 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹32 Cr ▼56.2% | ₹73 Cr ▲180.2% | ₹-91 Cr ▼51.7% | ₹-60 Cr ▼217.6% | ₹51 Cr ▲363.6% | ₹11 Cr ▼35.3% | ₹17 Cr ▼73.0% | ₹63 Cr ▲53.7% | ₹41 Cr ▼18.0% | ₹50 Cr |
| Investing CF | ₹-322 Cr ▼288.0% | ₹-83 Cr ▼76.6% | ₹-47 Cr ▼46.9% | ₹-32 Cr ▲54.3% | ₹-70 Cr ▼483.3% | ₹-12 Cr ▲7.7% | ₹-13 Cr ▲51.9% | ₹-27 Cr ▼92.9% | ₹-14 Cr ▲48.1% | ₹-27 Cr |
| Financing CF | ₹300 Cr ▲5900.0% | ₹5 Cr ▼96.5% | ₹144 Cr ▲118.2% | ₹66 Cr ▲40.4% | ₹47 Cr ▲840.0% | ₹5 Cr | ₹0 Cr ▲100.0% | ₹-38 Cr ▼58.3% | ₹-24 Cr ▲11.1% | ₹-27 Cr |
| Net Cash Flow | ₹10 Cr ▲300.0% | ₹-5 Cr ▼183.3% | ₹6 Cr ▲123.1% | ₹-26 Cr ▼192.9% | ₹28 Cr ▲600.0% | ₹4 Cr ▲0.0% | ₹4 Cr ▲500.0% | ₹-1 Cr ▼133.3% | ₹3 Cr ▲175.0% | ₹-4 Cr |
| Free Cash Flow | ₹-182 Cr ▼2175.0% | ₹-8 Cr ▲94.2% | ₹-137 Cr ▼7.9% | ₹-127 Cr ▼1370.0% | ₹10 Cr ▲266.7% | ₹-6 Cr ▼200.0% | ₹6 Cr ▼83.8% | ₹37 Cr ▲19.4% | ₹31 Cr ▼24.4% | ₹41 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65d ▼7.1% | 70d ▲2.9% | 68d ▲15.3% | 59d ▲5.4% | 56d ▼5.1% | 59d ▼7.8% | 64d ▼12.3% | 73d ▲28.1% | 57d ▼13.6% | 66d |
| Inventory Days | 94d ▲10.6% | 85d ▼2.3% | 87d ▼9.4% | 96d ▲17.1% | 82d ▼9.9% | 91d ▲31.9% | 69d ▼9.2% | 76d ▲16.9% | 65d ▲27.5% | 51d |
| Days Payable | 114d ▲12.9% | 101d ▲16.1% | 87d ▼3.3% | 90d ▼8.2% | 98d ▼13.3% | 113d ▼8.9% | 124d ▼28.3% | 173d ▲38.4% | 125d ▼10.7% | 140d |
| Cash Conv. Cycle | 45d ▼16.7% | 54d ▼21.7% | 69d ▲6.2% | 65d ▲62.5% | 40d ▲8.1% | 37d ▲311.1% | 9d ▲137.5% | -24d ▼700.0% | -3d ▲87.0% | -23d |
| Working Capital Days | 107d ▲13.8% | 94d ▼4.1% | 98d ▲78.2% | 55d ▲223.5% | 17d ▲312.5% | -8d ▲76.5% | -34d ▲45.2% | -62d ▲27.9% | -86d ▼760.0% | -10d |
| ROCE | 15.0% ▼11.8% | 17.0% ▲112.5% | 8.0% ▼65.2% | 23.0% ▲0.0% | 23.0% ▲130.0% | 10.0% ▲25.0% | 8.0% ▼11.1% | 9.0% ▲0.0% | 9.0% ▲12.5% | 8.0% |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Morepen Laboratories Limited share price today?▾
Morepen Laboratories Limited (MOREPENLAB) is currently trading at ₹42.63 on NSE, down 1.48% as of the last market session. Prices update daily after market close on MarketNetra.
Is Morepen Laboratories Limited available in F&O (Futures & Options)?▾
Yes, Morepen Laboratories Limited (MOREPENLAB) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Morepen Laboratories Limited 52-week high and low?▾
Morepen Laboratories Limited's 52-week high is ₹70.5 and the 52-week low is ₹33. The current price of ₹42.63 is 39.5% below the 52W high.
What is Morepen Laboratories Limited P/E ratio?▾
Morepen Laboratories Limited's current P/E ratio is 29.9. This indicates the market is paying ₹29.9 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Morepen Laboratories Limited options?▾
Morepen Laboratories Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade MOREPENLAB options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.